Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pre-pandemic influenza vaccine (HD-MAP)
- Development stage
- Unknown
- Lead developer
- Vaxxas
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Transdermal
01
Overview
This pre-pandemic avian influenza A (H7N9) vaccine is a clinical-stage candidate developed by Vaxxas using its proprietary high-density microarray patch (HD-MAP) technology. The HD-MAP platform utilizes thousands of vaccine-coated microscopic projections to deliver antigens directly to the abundant immune cells located just below the skin surface (epidermis and upper dermis). This transdermal delivery method is designed to be needle-free and potentially offers enhanced immunogenicity, dose-sparing effects, and improved thermostability compared to traditional needle-and-syringe injections. The vaccine specifically targets the H7N9 strain, identified by the WHO as a significant pandemic threat due to its high fatality rate. The development is supported by the Biomedical Advanced Research and Development Authority (BARDA) and is currently undergoing Phase 1 clinical evaluation to assess safety and immunogenicity in both adjuvanted and non-adjuvanted formulations.
- Other names
- H7N9 influenza vaccine (HD-MAP)Vaxxas H7N9 vaccinepre-pandemic avian influenza A (H7N9) vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on pre-pandemic influenza vaccine (HD-MAP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pre-pandemic influenza vaccine (HD-MAP).